# electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/ECOR/electrocore-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-9e1c60e4
Ticker: ECOR
Company: electroCore
Source: electroCore
Published: 2026-03-31 12:00 EST
## Summary

electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and...

## Article Body
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Seth Abrams will join electroCore, effective April 1, 2026, as the Company’s VP, Sales, and Michael Fox will join electroCore, effective April 13, 2026, as the Company's Chief Operating Officer. The Compensation Committee of electroCore’s Board of Directors granted 30,000 restricted stock units (“RSUs”) to Mr. Abrams and 70,000 RSUs to Mr. Fox in connection with the commencement of their employment. The RSUs were granted as an inducement material to their commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). In general, one-third of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to each individual's continued employment by the Company on the applicable vesting date. Upon vesting, the RSUs shall be settled in shares of the Company’s common stock.

About electroCore, Inc. electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to electroCore, Inc. and its subsidiaries (“electroCore” or the “Company”) is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation, or nVNS, and the Quell® Fibromyalgia. Additionally, the Company commercializes its handheld and personal use Trvuaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Contact: ECOR Investor Relations (973) 302-9253 investors@electrocore.com
## Recent Company News
- 2026-07-16 12:00 EST — [New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation](https://biopharmsignal.com/news/ECOR/new-review-examines-anatomical-and-methodological-differences-between-auricular--75858401) — Source: electroCore
- 2026-06-17 12:00 EST — [electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference](https://biopharmsignal.com/news/ECOR/electrocore-to-participate-in-iaccess-alpha-virtual-best-ideas-summer-investment-07437969) — Source: electroCore
- 2026-06-09 12:00 EST — [Frontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery](https://biopharmsignal.com/news/ECOR/frontiers-in-neuroscience-accepts-review-article-synthesizing-evidence-that-cerv-90a5568d) — Source: electroCore
- 2026-06-02 12:00 EST — [electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub](https://biopharmsignal.com/news/ECOR/electrocore-to-present-at-the-planet-microcap-las-vegas-2026-powered-by-microcap-9774a6c0) — Source: electroCore
- 2026-05-13 12:00 EST — [electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia](https://biopharmsignal.com/news/ECOR/electrocore-announces-publication-in-jama-highlighting-the-benefits-of-adding-qu-c4813dca) — Source: electroCore
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)